Relatively safe and effective therapeutic strategies such as vascular endothelial growth factor (VEGF) inhibitor, Epstein-Barr virus (EBV)-specific vaccines, along with novel immunotherapies targeting immune checkpoints may offer promising alternatives for elderly patients with locoregionally advanced NPC. Here, VEGFA is linked to nasopharyngeal carcinoma.